▎药明康德内容团队编辑
药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务,服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求,欢迎点击下方图片填写具体信息。
▲如您有任何业务需求,请长按扫描上方二维码,或点击文末“阅读原文/Read more”,即可访问业务对接平台,填写业务需求信息
参考资料:
[1] Phase 2b studies of investigational selective coagulation modulators fesomersen and osocimab in patients with advanced renal disease completed. Retrieved July 28, 2022, from https://media.bayer.de/baynews/baynews.nsf/id/Phase-studies-investigational-selective-coagulation-modulators-fesomersen-osocimab-patients-advanced?OpenDocument&sessionID=1659026520
[2] Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment. Retrieved July 28, 2022, from https://www.prnewswire.com/news-releases/ionis-announces-positive-topline-results-from-phase-2b-clinical-study-of-fesomersen-a-potential-novel-anti-thrombotic-treatment-301594902.html
版权说明:本文来自药明康德内容团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”,获取转载须知。
分享,点赞,在看,聚焦全球生物医药健康创新